Oncopeptides AB Stock price

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 07:13:58 2024-03-19 am EDT 5-day change 1st Jan Change
4.328 SEK +3.69% Intraday chart for Oncopeptides AB -24.20% -44.01%
Sales 2023 35.2M 3.36M Sales 2024 * 81.98M 7.82M Capitalization 395M 37.66M
Net income 2023 -249M -23.75M Net income 2024 * -213M -20.31M EV / Sales 2023 18.7 x
Net cash position 2023 66.92M 6.38M Net cash position 2024 * 220M 20.98M EV / Sales 2024 * 2.13 x
P/E ratio 2023
-2.78 x
P/E ratio 2024 *
-3.73 x
Employees 57
Yield 2023 *
-
Yield 2024 *
-
Free-Float 89.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.69%
1 week-24.20%
Current month-11.13%
1 month-41.88%
3 months-44.97%
6 months-45.94%
Current year-44.01%
More quotes
1 week
4.00
Extreme 4
5.30
1 month
4.00
Extreme 4
8.30
Current year
4.00
Extreme 4
8.30
1 year
4.00
Extreme 4
12.40
3 years
3.40
Extreme 3.402
162.50
5 years
3.40
Extreme 3.402
215.00
10 years
3.40
Extreme 3.402
215.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 20-07-31
Director of Finance/CFO 50 Nov. 12
Chief Tech/Sci/R&D Officer 42 19-10-31
Members of the board TitleAgeSince
Chairman 76 18-05-16
Director/Board Member 63 11-12-31
Director/Board Member 61 17-01-31
More insiders
Date Price Change Volume
24-03-19 4.288 +2.73% 75 120
24-03-18 4.174 +2.50% 261,246
24-03-15 4.072 -10.90% 869,982
24-03-14 4.57 -8.96% 420,124
24-03-13 5.02 -11.28% 1,463,061

Delayed Quote Nasdaq Stockholm, March 19, 2024 at 07:00 am EDT

More quotes
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company's lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.174 SEK
Average target price
6.8 SEK
Spread / Average Target
+62.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Oncopeptides AB - Nasdaq Stockholm